Venetoclax
API’s Name:Venetoclax
CAS No.:1257044-40-8
Indication:CLL
Innovator:Abbvie
Specification:
Patent Expiry Date(The U.S):Jun.27,2031
US DMF:
EU DMF:
CEP:
Only for R&D purpose
Product Detail
Intermediates
Code | CAS | Specification |
VCL-6A | 98549-88-3 | In-House |
VCL-7A | 1235865-75-4 | In-House |
VCLM2 | 1228780-72-0 | In-House |
VCLM2-2HCl | 1628047-87-9 | In-House |
VCLM3 | 1228779-96-1 | In-House |
Generic Name: venetoclax (ven ET oh klax)
Brand Name: Venclexta, Venclexta Starting Pack
Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic leukemia in adults. Venetoclax is used alone or in combination with other cancer medicines to treat these conditions.
Venetoclax is used in combination with azacitidine, decitabine, or cytarabine to treat acute myeloid leukemia. This combination is for use in adults who are 75 years or older, or who cannot use standard chemotherapy due to other medical conditions.
Venetoclax is sometimes given after other treatments have failed.
Venetoclax may also be used for purposes not listed in this medication guide.
Description
Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy.
In Vitro
Venetoclax (ABT-199) potently kills FL5.12-BCL-2 cells (EC50=4 nM), Venetoclax (ABT-199) shows much weaker activity against FL5.12-BCL-XL cells (EC50=261 nM). ABT-199 also shows selectivity in cellular mammalian two-hybrid assays, where it disrupts BCL-2-BIM complexes (EC50=3 nM) but is much less effective against BCL-XL-BCL-XS (EC50=2.2 μM) or MCL-1-NOXA complexes.
After a single oral dose of 12.5 mg per kg body weight in xenografts derived from RS4;11 cells (ALL), Venetoclax (ABT-199) causes a maximal tumor growth inhibition (TGImax) of 47% (P<0.001) and tumor growth delay (TGD) of 26% (P<0.05)[1].
Treatment of established xenografted (a mouse xenograft model of the T-ALL cell line LOUCY) tumors with Venetoclax (ABT-199) 100 mg/kg for 4 days results in a significant reduction of leukemic burden.
Storage
Powder | -20°C | 3 years |
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |